Filing Flows › Health Care › DarioHealth (DRIO)
DarioHealth (DRIO) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 11, 2026 · DarioHealth (DRIO) Q2 2026 earnings results →
Q2 2026 Revenue down 4% year over year to $5.2M · 153¢ of every $1 of revenue lost · operating margin -125.1%
DarioHealth made $5.2M in Q2 2026 (-4% Y/Y): Hardware and Consumable Products $2.6M, Services $2.6M. Operating margin -125.1%, net loss $7.9M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 11, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $5.2M in Q2 2026, down 4% year over year and down 7% from the previous quarter. Hardware and Consumable Products was the largest line at 50% of revenue. Services lost $1.1M year over year (down 29%), 560% of the total change.
Gross margin was 61.7%, up 6.5 points from Q2 2025. Operating costs exceeded revenue by $6.5M, an operating margin of -125.1%. Operating expenses fell 20% while revenue fell 4%. The quarter ended with a net loss of $7.9M, narrower than the previous quarter's $8.2M loss.
Operating cash flow was −$6.1M. Non-cash charges added back $515K of depreciation and amortization and $632K of share-based compensation. Working capital and other items added $694K. Capital expenditures of $38K exceeded it, leaving free cash flow of −$6.1M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 11, 2026 | $5.2M | -4% | -125.1% | −$7.9M | −$6.1M |
| Q1 2026 | 10-Q | May 13, 2026 | $5.6M | -17% | -130.9% | −$8.2M | −$6.0M |
| Q4 2025 | 10-K | Mar 19, 2026 | $5.2M | -31% | -163.7% | −$9.0M | −$5.9M |
| Q3 2025 | 10-Q | Nov 13, 2025 | $5.0M | -32% | -189.4% | −$10.5M | −$7.3M |
| Q2 2025 | 10-Q | Aug 12, 2025 | $5.4M | -14% | -171.4% | −$13.0M | −$6.0M |
| Q1 2025 | 10-Q | May 14, 2025 | $6.8M | +17% | -139.4% | −$9.2M | −$6.7M |
| Q4 2024 | 10-K | Mar 10, 2025 | $7.6M | +110% | -153.4% | −$9.6M | −$6.7M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Buys from
- AAPL · Stated in 10-K (named, share not stated) · source
- GOOGL · Stated in 10-K (named, share not stated) · source
About DarioHealth
We are a vertically integrated health intelligence platform with a mission to power the behavior changes that drive better health. Unlike software-only digital health platforms, Dario owns the complete chain of value in chronic care management - connected FDA-cleared hardware devices that generate continuous physiological data, AI built on that proprietary data, and a behavior change and coaching layer validated through over 100 peer-reviewed clinical studies. We are committed to transforming healthcare by delivering a comprehensive and highly engaging whole-person health platform, which enables us to create a future where healthy change is effortless and accessible to all.
In its own words, from its 10-K, filed Mar 19, 2026.
DarioHealth against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -4% against the peers' median +5%. Operating margin: -125.1% against the peers' median 13.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| DRIO DarioHealth | Q2 2026 | $5.2M | -4% | -125.1% |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: DarioHealth 10-Q on SEC EDGAR · CIK 1533998 · Surgical & Medical Instruments & Apparatus
13F: who owns DRIO and who is buying
More on DRIO
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results